Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Oncolytics Biotech ( (ONCY) ) has provided an update.
On March 2, 2026, Oncolytics Biotech Inc. announced the launch of REO 033, a randomized Phase 2 study in second-line RAS-mutated, microsatellite-stable metastatic colorectal cancer, comparing standard bevacizumab plus FOLFIRI to an experimental arm adding pelareorep, with 30 patients per arm and objective response rate as the primary endpoint. The trial, led by Rutgers Cancer Institute’s Dr. Sanjay Goel and expected to open its first site later in March with preliminary data targeted by year-end, aims to confirm earlier REO 022 results in the same population, where pelareorep-based therapy showed substantially improved survival and response rates over standard of care, underscoring pelareorep’s emerging role in colorectal cancer and potentially strengthening Oncolytics’ position in gastrointestinal oncology.
The most recent analyst rating on (ONCY) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Oncolytics Biotech stock, see the ONCY Stock Forecast page.
Spark’s Take on ONCY Stock
According to Spark, TipRanks’ AI Analyst, ONCY is a Neutral.
The score is held back primarily by weak financial performance (no revenue, sizable losses, heavy cash burn, and a sharply reduced equity base that raises financing risk). Technicals are a near-term positive with price above major moving averages and positive momentum indicators, while valuation remains difficult to support due to the negative P/E and lack of dividend.
To see Spark’s full report on ONCY stock, click here.
More about Oncolytics Biotech
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered double-stranded RNA immunotherapeutic agent designed to convert immunologically “cold” tumors “hot” by activating innate and adaptive immune responses. The company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic gastrointestinal cancers, where it has Fast Track designation from the FDA for colorectal and pancreatic cancer and is seeking strategic partnerships to accelerate development and commercialization.
Average Trading Volume: 1,275,160
Technical Sentiment Signal: Buy
Current Market Cap: $121.6M
For detailed information about ONCY stock, go to TipRanks’ Stock Analysis page.